The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.本發明提供特異性結合至TIGIT之單株抗體。該等單株抗體具有藉由抑制TIGIT與CD155之結合而大量活化T細胞及自然殺手細胞的能力。該等單株抗體在其他應用當中可用於治療癌症及傳染病。